XTalks

NOVEMBER 12, 2024

Pneumonia is a lung infection that can be caused by viruses, bacteria or fungi and can result in millions of hospitalizations and deaths annually. For example, recent clinical trials and regulatory approvals for RSV vaccines are notable milestones that indicate advancements in preventing viral pneumonia in both children and elderly adults.

Bacteria 110

Bacteria Life Science Vaccination Vaccine 110

Medical Xpress

NOVEMBER 25, 2022

A team of researchers at Duke University has developed a vaccine against uropathogenic E. coli (UPEC), the type of bacteria that cause urinary tract infections (UTIs) in humans.

Bacteria 98

Bacteria Vaccination Vaccine Development 98

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccination 195

Vaccination Vaccine Immune Response Bacteria 195

Scienmag

JUNE 2, 2022

An investigation into the evolution of Salmonella bacteria infecting Brazilian poultry shows that the introduction of a Salmonella vaccine, combined with increasing antibiotic usage by Brazilian farmers, has led to the rise of strains that are more antibiotic-resistant, but less likely to cause disease in humans.

Bacteria 78

Bacteria Vaccination Vaccine 78

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

Scienmag

JULY 7, 2021

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species.

Bacteria 75

Bacteria Bacterium Immune Response Vaccination 75

Scienmag

NOVEMBER 9, 2020

— Similar to bacteria evolving resistance to antibiotics, viruses can evolve resistance to vaccines, and the evolution of SARS-CoV-2 could undermine the effectiveness of vaccines that are currently under development, according to a paper published November 9 in the open-access journal PLOS […]. UNIVERSITY PARK, Pa.

Vaccination 98

Vaccination Vaccine Bacteria Development 98

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

Pharma Times

DECEMBER 20, 2023

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. The initiative aims to create new or improved vaccines for deadly respiratory diseases, including tuberculosis (TB) and influenza. million deaths every year.

Vaccination 110

Vaccination Vaccine Immune Response Bacteria 110

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 22, 2022

The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.

Vaccination 100

Vaccination Vaccine Research Bacteria 100

Scienmag

JULY 8, 2021

A new vaccine technology combining capture of bacterial pathogens with effective immune-reprogramming biomaterials could be applied to a broad spectrum of infectious diseases Credit: Wyss Institute at Harvard University.

Vaccination 98

Vaccination Vaccine Bacteria Drugs 98

Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccination 88

Vaccination Vaccine Bacteria Development 88

XTalks

JUNE 21, 2024

The US Food and Drug Administration (FDA) has green-lighted the first pneumonia vaccine specifically designed for adults 50 years of age and older. These numbers do not reflect the efficacies of the vaccines, which have not been compared head-to-head in any trial yet.

FDA Approval 108

FDA Approval Vaccination Vaccine Life Science 108

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

XTalks

AUGUST 17, 2022

August is National Immunization Awareness Month (NIAM), which is marked to help raise awareness about the importance of vaccines in the protection of public health. One of the themes of this year’s National Immunization Awareness Month is “vaccines work.” Vaccination Awareness from the FDA.

Vaccination 98

Vaccination Vaccine Bacteria Development 98

NPR Health - Shots

NOVEMBER 9, 2022

Several crises in the country — including political instability, COVID and financial collapse — have created deteriorating conditions that have allowed the bacteria to spread. Image credit: Ari Daniel/NPR)

Bacteria 98

Bacteria Vaccination Vaccine 98

XTalks

JULY 25, 2023

Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). anthracis , primarily affecting livestock and wild game.

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

Scienmag

MAY 9, 2021

Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores.

Bacteria 49

Bacteria Vaccination Vaccine Research 49

Pharmaceutical Technology

DECEMBER 21, 2023

This innovative composition induces a protective immune response against Group A Streptococcus (GAS) bacteria, offering potential targets for vaccine development. Discover a groundbreaking immunogenic composition patent that combines GAS polypeptide antigens and polypeptide-polysaccharide conjugates.

Immune Response 100

Immune Response Bacteria Vaccination Vaccine 100

XTalks

DECEMBER 23, 2024

Meanwhile, expanded malaria vaccine access in 17 countries offers hope, poised to save tens of thousands of lives annually. Preparing for these events involves strengthening early detection systems, expanding vaccine distribution networks and addressing critical public health gaps. AI continues to play a growing role.

Vaccine 52

Vaccine Vaccination Containment Bacteria 52

Medical Xpress

DECEMBER 23, 2022

Formed in response to infection and vaccination, these microscopic training grounds allow B cells to perfect the antibodies they deploy against specific viruses and bacteria.

Bacteria 104

Bacteria Antibody Manufacturing Vaccine 104

Medical Xpress

MARCH 1, 2025

Often the perpetrators are viruses and bacteria you've conquered; others are undercover agents like vaccines given to trigger protective immune responses or even red herrings in the form of healthy tissue caught in immunological crossfire.

Immune Response 93

Immune Response Bacteria Vaccine Vaccination 93

Scienmag

JUNE 10, 2022

Researchers have known for some time that maternal breast milk provides critical nutrients for newborns, and antibodies from mothers vaccinated against a specific disease-causing bacterium or virus can be transferred via breast milk to babies.

Antibody 72

Antibody Bacteria Bacterium Vaccine 72

STAT News

SEPTEMBER 30, 2022

The shortlist includes researchers who elucidated how cells make energy, those who discovered the chemical chatter of bacteria, many of the brilliant minds who shepherded us into the “ era of the genome ,” and most prominently, the pioneers behind the mRNA Covid vaccines. Read the rest…

Bacteria 124

Bacteria Genome Genomics Vaccination 124

pharmaphorum

NOVEMBER 25, 2020

AstraZeneca’s research chief has said that the more effective dosing regimen of its coronavirus vaccine was discovered by accident. According to Reuters , the AstraZeneca development team made a minor mistake that made them realise they could significantly boost the success rate of the vaccine, codenamed AZD1222.

Vaccine 119

Vaccine Vaccination Bacteria RNA 119

BioSpace

OCTOBER 19, 2020

In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease.

Bacteria 74

Bacteria Trials Vaccination Vaccine 74

Delveinsight

JULY 27, 2021

GlaxoSmithKline announced the US Food and Drug Administration approval for its vaccine, Shingrix (Zoster Vaccine Recombinant, Adjuvanted) under trials in 18+ adults who are vulnerable or at an increased risk to Shingles , which is already commercialized for patient group aged 50 and above.

Vaccination 96

Vaccination Vaccine Trials Manufacturing 96

Pfizer

FEBRUARY 16, 2023

who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy, safety and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15. OspA is a surface protein expressed by the bacteria when present in a tick.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

pharmaphorum

MAY 11, 2022

A greater threat is the emerging bacteria that are resistant to multiple or all existing anti-bacterial agents. As these bacteria spread more broadly, new antimicrobial treatments are in even greater need of development. Second, prevent infections wherever possible, including with vaccines. Why AMR is a threat.

Bacteria 145

Bacteria Development Production Vaccine 145

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The post GSK bolsters vaccines division with $3.3bn swoop on Affinivax appeared first on. GlaxoSmithKline has agreed a $3.3

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

The Pharma Data

MARCH 8, 2021

Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. It will compare the three-dose vaccination schedule (Month 0-2-6) with a two-dose schedule (Month 0-6). “We We are excited to be part of the Lyme disease vaccine development program with Valneva.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

Delveinsight

JULY 26, 2021

Often the bacteria develop antibiotic resistance to certain drugs, leaving it non-effective for the usage the second time in the case of recurrence of the infection that occurs in approximately 30-35% of the uUTI cases, therefore, leaving a serious dearth of the new antibiotics. coli bacteria called FimH.

Marketing 93

Marketing Bacteria Development Vaccine 93

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D.,

Vaccination 52

Vaccination Vaccine Trials Bacteria 52